Gakya123 wrote: We, the investors, are getting Nothing but GOOD NEWS!
Here is a summary of the all the NR’s we have gotten this past month …. ONE MONTH! Obviously, the team at Isodiol is working around the clock to ensure the company is a success. I am invested in other stocks as well, but honestly, Isodiol is my “baby”. I know, I know … they say “don’t fall in love with a stock” … well, too late! I am heads over heels in love with the company. LOL
If you still don’t believe in the company after all these news, then here is my suggestion: sell, leave, and don’t come back! Lol
Posted on November 21, 2017 November 22, 2017 Isodiol News: Isodiol International Inc. Upgrades to OTCQB “We are very pleased with this OTCQB listing. Listing on the OTCQB is part of Isodiol’s overall strategy to increase awareness to international investors,” said Marcos Agramont, CEO of Isodiol. “This listing will provide the Company with a significant trading platform for international shareholders and future investors, while making the Company itself easily available to American investors.”
Posted on 7 Isodiol International Inc. Signs Definitive Agreement to Acquire Bradley’s Bioscience Inc., and Closes Strategic Financing “The acquisition of Bradley’s Bioscience, a market poised to be a $61.4 billion-dollar industry by 2025 is another major milestone for the Company,” said Marcos Agramont, CEO of Isodiol. “Not only does this allow the Company to penetrate a new market, but we are now also able to provide consumers with a safer alternative to smoking. Overall, we believe Bradley’s Bioscience is a perfect fit with Isodiol and our long-term vision, and we are very pleased to be moving forward with this agreement.”
Posted on November 24, 2017 November 24, 2017 Isodiol International Inc Signs Binding Agreement to Acquire 100% of C3 Global Biosciences “Isodiol and C3GBS are truly complementary. We look forward to bringing the C3GBS brand and world-class team onboard to pursue the shared vision of providing consumers with the highest quality of bioactive CBD products,” said Marcos Agramont, CEO of Isodiol. “By combining the two companies, we can align our efforts strategically to further strengthen our portfolio of assets. This partnership will be aimed at increasing market expertise as we establish both companies as leaders in the CBD market.”
Posted on November 29, 2017 November 29, 2017 Isodiol International Inc. Announces Appointment of Dr. Ronald Aung-Din as an Advisor, Closes Strategic Financing Dr. Aung-Din, a board-certified neurologist with more than 25 years of practice in general neurology and neuro-psychiatry, joins Isodiol after pioneering significant scientific advancements in the medical community. During his tenure, Dr. Aung-Din participated in more than 60 pharmaceutical-sponsored studies that proved to be instrumental in the development of numerous drugs for utilization and treatment of degenerative and neurological conditions. In this role, Dr. Aung-Din will aid in the development of a series of new products designed to have a profound impact on the daily lives of those suffering from symptoms of peripheral neuropathy, cluster headaches, migraines, Parkinson’s disease, multiple sclerosis, and other debilitating conditions.
Posted on December 1, 2017 Isodiol International Inc. Signs Binding Agreement to Acquire 100% Stake in Be Tr Organics™ “Isodiol and Be Tr share the common goal of providing consumers with high-quality products that promote physical and mental well-being,” said Marcos Agramont, CEO of Isodiol. “This strategic partnership would further enable us to diversify our product offerings, thus generating additional revenue streams. With both companies committed to being at the forefront of product innovation, this acquisition was an easy decision for us.”
Posted on December 6, 2017 December 16, 2017 Isodiol International Inc. Announces Binding Agreement to Acquire 25% of Canadian National Pharma Group Inc. “As a supplier of raw materials and active pharmaceutical ingredients, our company prides itself on its quality and standards, supplier selection process, audits, and inspections,” said Marcus Dahl, President, and CEO of CN Pharma. “We strongly believe this partnership will help elevate CN Pharma to new levels through additional capital investments into our infrastructure growth and expansion of facilities, equipment, and services.”
Posted on 7 I SODIOL INTERNATIONAL INC. TO PRESENT, EXHIBIT AT 25TH ANNUAL AMERICAN ACADEMY OF ANTI-AGING MEDICINE WORLD CONGRESS DECEMBER 7, 2017 – LAS VEGAS – Isodiol International Inc. (
CSE:
ISOL) (
OTC:
ISOLF) (
FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that Dr. Ronald Aung-Din, Medical, Science and Development Advisor at Isodiol, will present at the 25th Annual American Academy of Anti-Aging Medicine (A4M) World Congress being held at the Venetian/Palazzo Resort in Las Vegas, December 14-16.
Posted on 7 Isodiol International Inc. Signs Definitive Agreement to Acquire 100% of Be Tr Organics™ “The acquisition with Be Tr Organics is yet another major milestone for Isodiol and we are very pleased to have been able to finalize this partnership so quickly,” said Marcos Agramont, CEO of Isodiol. “Not only does this partnership add diversity to the Isodiol’s already strong portfolio of products, but gives the Company access to the mainstream distribution channels that Be Tr Organics has been able to penetrate.”
Posted on December 8, 2017 December 16, 2017 Isodiol International Inc. Executes Definitive Agreement to Acquire 100% of C3 Global Biosciences™ “At Isodiol, we believe that the ideation, creation, and evaluation of new ideas is an interconnected process that drives innovation forward,” said Marcos Agramont, CEO of Isodiol. “C3GBS’s world-class team has a clear mission, focused strategy and healthy culture – all of which we expect will support the creation of value over the long term for Isodiol, our shareholders, and society.”
Posted on December 13, 2017 December 16, 2017 Isodiol International Inc. Provides Update on Be Tr Organics™, Announces New Distribution Channel “We are always looking for new ways to expand our company’s reach and further diversify our product offerings,” said Marcos Agramont, CEO of Isodiol. “We closed the 100% acquisition of Be Tr last week, and in this short amount of time, we have already seen strong results from this partnership. This partnership will continue to open additional revenue streams, and enable Isodiol to penetrate the mainstream market and provide consumers with natural, high-quality, health and wellness products.”
Posted on December 14, 2017 December 16, 2017 Isodiol International Inc. Initiates Implementation of Blockchain Technology for Payment Processing “The Isodiol customer experience is always a priority for us and accepting bitcoin seemed to be a natural implementation, as we want to ensure that our customers have choices as to how they shop and ultimately have the best experience possible,” said Marcos Agramont, CEO of Isodiol. “In Phase 2 of the implementation, which takes place in the first quarter of 2018, we anticipate cryptocurrency acceptance across all of Isodiol’s family of brands.”
Posted on December 15, 2017 December 16, 2017 Isodiol International Acquires Global Rights to Produce Products Under an Innovative Delivery System Patent “This is another monumental step taken by Isodiol and C3GBS to be the global leader in cannabis research, science, innovation, and technology to positively impact patient outcomes. The EEG system offers another diagnostic tool, that is FDA approved, to help understand how cannabis is beneficial to the human body,” added Isodiol CEO,
Marcos Agramont.
Posted on December 17, 2017 Isodiol International Inc. Announces Binding Agreement to Acquire Biosynthesis Pharma Group “It has been a part of Isodiol’s growth strategy to aggressively pursue international expansion. Through this acquisition, the company is aligned to penetrate foreign markets particularly in the United Kingdom, Europe, Asia, South and Central America. We will broaden our product availability and make the most bioactive cannabinoid products available on a global scale. This acquisition puts us at the forefront of global cannabinoid clinical research and studies which will complement our current efforts in Brazil and other markets we are presently developing,” said Marcos Agramont, CEO of Isodiol.
Posted on December 19, 2017 December 19, 2017 Isodiol International Inc. Announces Strategic $30,000,000 CAD Financing Aaron Nathaniel Serruya of Serruya Equity stated, “We are pleased to participate in yet another round of funding for Isodiol. Isodiol continues to impress us with innovation and global reach. We expect great things from the Company, including their recent successful launch of a non-cannabis based CBD derived from two specific strains of hops and their pending acquisition of Biosynthesis Pharma Group.”